Novo Nordisk 's high-dose experimental obesity pill helped overweight or obese adults lose around 15% of their body weight, according to new late-stage clinical trial results.
Novo Nordisk told Reuters it plans to file for Food and Drug Administration approval of the drug later this year.
But the highest dose of Rybelsus is 14 milligrams, while the company's experimental obesity pill has a far larger dose of 50 milligrams.
Other companies are also developing oral weight loss treatments to appeal to those who don't want weekly injections.
Pfizer is also developing its own weight loss pill, called danuglipron, which patients take twice a day.
Persons:
Eli Lilly, Dr, Filip Knop, Knop, Eli Lilly's, Elon Musk
Organizations:
Novo Nordisk, Reuters, Food and Drug, Pfizer, University of Copenhagen, Novo, Companies, Novo Nordisk's Ozempic, National Institutes of Health
Locations:
Danish